Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer - PubMed (original) (raw)

Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer

Yu Yuecheng et al. Clin Exp Metastasis. 2006.

Abstract

E-cadherin plays an important role in maintaining tissue architecture. Loss of E-cadherin expression has often been associated with cancer metastasis. This study assessed the immuno-expression of E-cadherin and methylation of CDH1 and correlated them with clinical features in primary epithelial ovarian cancer. Moreover, epithelial ovarian cancer cell SKOV3 was used to explore the mechanism how the demethylating agent 5-Aza inhibited cancer metastasis. Of 80 patients with primary ovarian cancer, we found that decreased immunoexpression pattern of E-cadherin was associated with clinical stage, lymph node metastasis, and degree of differentiation. Methylation of CDH1 detected by MSP occurred frequently and was correlated with reduced expression of E-cadherin protein. 5-Aza treatment could lead to re-expression of functional E-cadherin, followed by decreased MMP-2 and MMP-9 activity and inhibition of cell invasion in SKOV3 cells. Therefore, we conclude that assessment of E-cadherin immunoreactivity or methylation of CDH1 may be a useful prognostic indicator in ovarian cancer, complementary to established prognostic factors. The mechanism underlying 5-Aza's anti-metastasis activity is associated with restored functional expression of E-cadherin and decreased MMPs activity. Correction of aberrant DNA methylation by 5-Aza may provide a new strategy for ovarian cancer prevention and therapy.

PubMed Disclaimer

Similar articles

• [E-cadherin promoter methylation and demethylation in epithelial ovarian carcinoma cells].
  Qu PP, Shi Z, Li N. Qu PP, et al. Zhonghua Fu Chan Ke Za Zhi. 2009 Jul;44(7):538-41. Zhonghua Fu Chan Ke Za Zhi. 2009. PMID: 19957556 Chinese.
• The reinforcement of invasion in epithelial ovarian cancer cells by 17 beta-Estradiol is associated with up-regulation of Snail.
  Ding JX, Feng YJ, Yao LQ, Yu M, Jin HY, Yin LH. Ding JX, et al. Gynecol Oncol. 2006 Nov;103(2):623-30. doi: 10.1016/j.ygyno.2006.04.023. Epub 2006 Jun 27. Gynecol Oncol. 2006. PMID: 16806441
• Clinical importance and therapeutic implication of E-cadherin gene methylation in human ovarian cancer.
  Wu X, Zhuang YX, Hong CQ, Chen JY, You YJ, Zhang F, Huang P, Wu MY. Wu X, et al. Med Oncol. 2014 Aug;31(8):100. doi: 10.1007/s12032-014-0100-y. Epub 2014 Jun 29. Med Oncol. 2014. PMID: 24973953
• Epigenetic versus genetic alterations in the inactivation of E-cadherin.
  Strathdee G. Strathdee G. Semin Cancer Biol. 2002 Oct;12(5):373-9. doi: 10.1016/s1044-579x(02)00057-3. Semin Cancer Biol. 2002. PMID: 12191636 Review.
• E-cadherin deregulation in breast cancer.
  Corso G, Figueiredo J, De Angelis SP, Corso F, Girardi A, Pereira J, Seruca R, Bonanni B, Carneiro P, Pravettoni G, Guerini Rocco E, Veronesi P, Montagna G, Sacchini V, Gandini S. Corso G, et al. J Cell Mol Med. 2020 Jun;24(11):5930-5936. doi: 10.1111/jcmm.15140. Epub 2020 Apr 16. J Cell Mol Med. 2020. PMID: 32301282 Free PMC article. Review.

Cited by

• Epigenetic therapies for chemoresensitization of epithelial ovarian cancer.
  Matei DE, Nephew KP. Matei DE, et al. Gynecol Oncol. 2010 Feb;116(2):195-201. doi: 10.1016/j.ygyno.2009.09.043. Epub 2009 Oct 24. Gynecol Oncol. 2010. PMID: 19854495 Free PMC article. Review.
• Activin B promotes endometrial cancer cell migration by down-regulating E-cadherin via SMAD-independent MEK-ERK1/2-SNAIL signaling.
  Xiong S, Klausen C, Cheng JC, Leung PC. Xiong S, et al. Oncotarget. 2016 Jun 28;7(26):40060-40072. doi: 10.18632/oncotarget.9483. Oncotarget. 2016. PMID: 27223076 Free PMC article.
• The association between CDH1 promoter methylation and patients with ovarian cancer: a systematic meta-analysis.
  Wang Q, Wang B, Zhang YM, Wang W. Wang Q, et al. J Ovarian Res. 2016 Apr 11;9:23. doi: 10.1186/s13048-016-0231-1. J Ovarian Res. 2016. PMID: 27067410 Free PMC article.
• CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients.
  Heinze K, Rengsberger M, Gajda M, Jansen L, Osmers L, Oliveira-Ferrer L, Schmalfeldt B, Dürst M, Häfner N, Runnebaum IB. Heinze K, et al. Clin Epigenetics. 2021 Jan 22;13(1):15. doi: 10.1186/s13148-021-01006-8. Clin Epigenetics. 2021. PMID: 33482905 Free PMC article.
• MT1-MMP is the critical determinant of matrix degradation and invasion by ovarian cancer cells.
  Sodek KL, Ringuette MJ, Brown TJ. Sodek KL, et al. Br J Cancer. 2007 Aug 6;97(3):358-67. doi: 10.1038/sj.bjc.6603863. Epub 2007 Jul 3. Br J Cancer. 2007. PMID: 17609667 Free PMC article.

References

1. 1. Hum Pathol. 1997 Aug;28(8):922-8 - PubMed
2. 1. Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 - PubMed
3. 1. Hum Pathol. 2004 Dec;35(12):1469-76 - PubMed
4. 1. Hum Pathol. 2004 Jun;35(6):663-9 - PubMed
5. 1. Breast Cancer Res. 2002;4(1):5-8 - PubMed

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal